Strategies to reduce SNCA levels may however still be appropriate for some forms of PD, including PARK 1 and 4, where there is an increased SNCA expression, or for individuals with SNCA risk variants that alter its expression, if not for general PD or familial forms without Lewy body pathology. This evidence concerns the gene SNCA and Parkinson disease.